AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics. Market participants are assessing the implications for related sectors and asset prices. Analysts note that this development may influence near-term trading sentiment and positioning across equities, rates, and commodities.
Meridian View
Meridian Intelligence View
Meridian Intelligence view: The AI boom is entrepreneurial action chasing marginal returns from new tech. Capital inflows inflate valuations; only services consumers willingly pay for represent genuine productivity progress.